Figure 4From: An overview of harms associated with β-lactam antimicrobials: where do the carbapenems fit in?Cumulative risk for emergence of Gram-negative resistant organisms by treatment and duration of hospitalization. Adapted with permission [70]. Copyright © 2001 the Infectious Diseases Society of America.Back to article page